Bimagrumab Phase 2 trial (NCT05616013)
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 507
- actual
- Start
- 16 Nov 2022 (actual)
- Primary completion
- 16 May 2024 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo/30 mg/kg Bimagrumab | Placebo comparator | Other: Placebo | Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 milligrams per kilogram (mg/kg) bimagrumab at Weeks 52 and 64. |
| 10/30 mg/kg Bimagrumab | Experimental | Biological: Bimagrumab | Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, and 40, followed by intravenous 30 mg/kg bimagrumab at Weeks 52 and 64. |
| 30 mg/kg Bimagrumab | Experimental | Biological: Bimagrumab | Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64. |
| Placebo + 1.0 mg Semaglutide | Experimental | Drug: Semaglutide; Other: Placebo | Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 1.0 milligram (mg) semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg |
| Placebo + 2.4 mg Semaglutide | Experimental | Drug: Semaglutide; Other: Placebo | Participants received intravenous placebo at baseline and at Weeks 4, 16, 28, 40 and subcutaneous 2.4 mg semaglutide weekly per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg |
| 10 mg/kg Bimagrumab + 1.0 mg Semaglutide | Experimental | Biological: Bimagrumab; Drug: Semaglutide | Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg |
| 10 mg/kg Bimagrumab + 2.4 mg Semaglutide | Experimental | Biological: Bimagrumab; Drug: Semaglutide | Participants received intravenous 10 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg |
| 30 mg/kg Bimagrumab + 1.0 mg Semaglutide | Experimental | Biological: Bimagrumab; Drug: Semaglutide | Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 1.0 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 71: 1.0 mg |
| 30 mg/kg Bimagrumab + 2.4 mg Semaglutide | Experimental | Biological: Bimagrumab; Drug: Semaglutide | Participants received intravenous 30 mg/kg bimagrumab at baseline and at Weeks 4, 16, 28, 40, 52, and 64, and subcutaneous 2.4 mg semaglutide weekly as per the below dose escalation schedule: * Weeks 1 to 4: 0.25 mg * Weeks 5 to 8: 0.5 mg * Weeks 9 to 12: 1.0 mg * Weeks 13 to 16: 1.7 mg * Weeks 17 to 71: 2.4 mg |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change From Baseline in Body Weight at Week 48 | Baseline, Week 48 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change From Baseline in Waist Circumference at Week 48 | Baseline, Week 48 |
| Change From Baseline in Waist Circumference at Week 72 | Baseline, Week 72 |
| Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48 | Baseline, Week 48 |
| Change From Baseline in Total Body Fat Mass in kg at Week 72 | Baseline, Week 72 |
| Percent Change From Baseline for Fat Mass by DXA at Week 48 | Baseline, Week 48 |
| Percent Change From Baseline for Fat Mass by DXA at Week 72 | Baseline, Week 72 |
| Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48 | Baseline, Week 48 |
| Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72 | Baseline, Week 72 |
| Percentage of Participants With Reduction in Waist Circumference Greater Than or Equal to (≥) 5 cm at Week 48 | Week 48 |
| Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 | Week 48 |
| Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48 | Week 48 |
| Percentage of Participants Achieving Fat Mass ≥ 10% Reduction With <5% Decrease in Lean Mass by DXA at Week 48 | Week 48 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05616013.
Week 48 body weight results posted for the bimagrumab and semaglutide study
The posted primary outcome is the change from baseline in body weight at week 48.[1]
Outcome group OG008 is labelled 30 mg/kg Bimagrumab + 2.4 mg Semaglutide.[1]
Outcome group OG004 is labelled Placebo + 2.4 mg Semaglutide.[1]
The posted least-squares mean change for outcome group OG004 (placebo plus semaglutide) was -14.24 kg, with a spread of 1.17.[1]
The posted change for outcome group OG008 (the highest bimagrumab level combined with semaglutide) was -17.79 kg, with a spread of 1.29.[1]
Sources
- 1A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and WomenClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.